(Q41728781)

8 October 2017

title

Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma (English)

1 reference

8 October 2017

1 reference

Wolfe J

1

1 reference

8 October 2017

Kreitzer S

2

1 reference

8 October 2017

Chervinsky P

3

1 reference

8 October 2017

Lawrence M

4

1 reference

8 October 2017

Wang Y

5

1 reference

8 October 2017

Reilly D

6

1 reference

8 October 2017

Davis S

7

1 reference

8 October 2017

Stahl E

8

1 reference

8 October 2017

publication date

1 March 2000

1 reference

Annals of Allergy, Asthma & Immunology

8 October 2017

published in

1 reference

8 October 2017

volume

84

1 reference

8 October 2017

issue

3

1 reference

8 October 2017

page(s)

334-340

1 reference

A Single-dose Comparison of Inhaled Albuterol and Two Formulations of Salmeterol on Airway Reactivity in Asthmatic Subjects

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

The use of beta-agonists and the risk of death and near death from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Assessment of Tachyphylaxis following Prolonged Therapy of Asthma with Inhaled Albuterol Aerosol

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Comparison of DiskusTMInhaler, a New Multidose Powder Inhaler, with DiskhalerTMInhaler for the Delivery of Salmeterol to Asthmatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Efficacy and safety of salmeterol in childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Comparison of salmeterol with disodium cromoglycate in the treatment of adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

A 1-week dose-ranging study of inhaled salmeterol in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

Whither beta-adrenergic tachyphylaxis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962783-4

7 January 2021

10.1016/S1081-1206(10)62783-4

Identifiers

DOI

1 reference

8 October 2017

1 reference